Literature DB >> 27650062

Granulocyte whole exome sequencing and endothelial JAK2V617F in patients with JAK2V617F positive Budd-Chiari Syndrome without myeloproliferative neoplasm.

Ricardo Helman1, Welbert de O Pereira2, Luciana C Marti3, Paulo V Campregher4, Renato Davi Puga5, Nelson Hamerschlak6, Carlos S Chiattone7, Fabio Pires de S Santos8.   

Abstract

Entities:  

Keywords:  Budd-Chiari syndrome; JAK2; endothelial cells; myeloproliferative neoplasms

Mesh：

Substances：

Year:  2016        PMID： 27650062     DOI： 10.1111/bjh.14327

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  12 in total

1.  Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension.

Authors:  Christopher R Reilly; Daria V Babushok; Karlyn Martin; Jerry L Spivak; Michael Streiff; Ranjeeta Bahirwani; Jeffrey Mondschein; Brady Stein; Alison Moliterno; Elizabeth O Hexner
Journal:  Am J Hematol       Date:  2017-07-26       Impact factor: 10.047

Review 2.  Megakaryocytes as the Regulator of the Hematopoietic Vascular Niche.

Authors:  Huichun Zhan; Kenneth Kaushansky
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

3.  JAK2V617F mutant endothelial cells promote neoplastic hematopoiesis in a mixed vascular microenvironment.

Authors:  Christopher Mazzeo; Moqing Quan; Helen Wong; Melissa Castiglione; Kenneth Kaushansky; Huichun Zhan
Journal:  Blood Cells Mol Dis       Date:  2021-05-31       Impact factor: 2.372

Review 4.  Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.

Authors:  Brandi N Reeves; Joan D Beckman
Journal:  Curr Hematol Malig Rep       Date:  2021-04-19       Impact factor: 4.213

5.  Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis.

Authors:  Alexandre Guy; Anicee Danaee; Koralia Paschalaki; Lisa Boureau; Etienne Rivière; Gabriel Etienne; Olivier Mansier; Michael Laffan; Mallika Sekhar; Chloe James
Journal:  Hemasphere       Date:  2020-05-05

6.  Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression.

Authors:  Alexandre Guy; Virginie Gourdou-Latyszenok; Nicolas Le Lay; Claire Peghaire; Badr Kilani; Juliana Vieira Dias; Cécile Duplaa; Marie-Ange Renault; Cécile Denis; Jean Luc Villeval; Yacine Boulaftali; Martine Jandrot-Perrus; Thierry Couffinhal; Chloe James
Journal:  Haematologica       Date:  2018-08-31       Impact factor: 9.941

7.  A Murine Model With JAK2V617F Expression in Both Hematopoietic Cells and Vascular Endothelial Cells Recapitulates the Key Features of Human Myeloproliferative Neoplasm.

Authors:  Haotian Zhang; Amar Yeware; Sandy Lee; Huichun Zhan
Journal:  Front Oncol       Date:  2021-10-26       Impact factor: 5.738

8.  Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm.

Authors:  Johanne Poisson; Marion Tanguy; Hortense Davy; Fatoumata Camara; Marie-Belle El Mdawar; Marouane Kheloufi; Tracy Dagher; Cécile Devue; Juliette Lasselin; Aurélie Plessier; Salma Merchant; Olivier Blanc-Brude; Michèle Souyri; Nathalie Mougenot; Florent Dingli; Damarys Loew; Stephane N Hatem; Chloé James; Jean-Luc Villeval; Chantal M Boulanger; Pierre-Emmanuel Rautou
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

9.  Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm.

Authors:  Melissa Castiglione; Ya-Ping Jiang; Christopher Mazzeo; Sandy Lee; Juei-Suei Chen; Kenneth Kaushansky; Wei Yin; Richard Z Lin; Haoyi Zheng; Huichun Zhan
Journal:  J Thromb Haemost       Date:  2020-10-05       Impact factor: 16.036

Review 10.  The possible role of mutated endothelial cells in myeloproliferative neoplasms.

Authors:  Mirko Farina; Domenico Russo; Ronald Hoffman
Journal:  Haematologica       Date:  2021-11-01       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.